

Why FebriDx?

Because urgent care and ER are the front lines of healthcare.



Fast and easy results after 10 minutes using a fingerstick



Helps to rule out bacterial infection with 99% NPV¹



Supports confident decision-making at the point of care



Instrument-free and fully portable



Intended for patients aged 12–64 with symptoms ≤ 7 days



Let's elevate point-of-care diagnostics together.

FebriDx is changing how frontline providers approach respiratory infection care in urgent care and emergency settings.

As healthcare regulations and guidelines continue to evolve, now is an ideal time to explore how rapid point-of-care diagnostics can empower your team to deliver faster, more informed decisions. This can help improve patient outcomes, reduce unnecessary antibiotic use, and support broader antimicrobial stewardship goals.

PHASESCIENTIFIC

Partner with us

-  phasescientificamericas.com
-  1-877-934-9344
-  USsales@phasesci.com
-  10527 Garden Grove Blvd
Garden Grove, California 92843

Distributed in partnership with Lumos Diagnostics

STAY IN TOUCH



FebriDx

Bacterial or not?



Get clear answers
after 10 minutes.

PHASESCIENTIFIC



Stop guessing. Start guarding.

Every year in the U.S., millions of antibiotic prescriptions are written for respiratory infections that aren't bacterial¹. This contributes to the rise of antimicrobial resistance (AMR), a growing public health crisis.


FebriDx empowers POC teams to play a critical role in antimicrobial stewardship.

By identifying whether an infection is likely bacterial or non-bacterial after 10 minutes, FebriDx helps reduce unnecessary antibiotic use and ensures patients receive the right care, right away.

- Supports responsible prescribing protocols
- Helps combat antibiotic overuse and resistance
- Strengthens pharmacy-based test-to-treat programs

Let's raise the bar for point-of-care clarity and protect antibiotic effectiveness for future generations.

Differentiate bacterial from non-bacterial ARI at the point of care



Ideal for point-of-care test-to-treat models.

Cold and flu symptoms + Fever, cough, sore throat + Nasal or chest congestion + Shortness of breath

1

Collect a fingerstick blood sample
(lancet included in device)




2

Transfer the blood to the test strip
via capillary action




3

Push the buffer release button down
completely until it clicks



4

Read results after 10 minutes



Scan the QR code to view our in-depth instructions for use.

FebriDx is FDA 510(k) cleared for prescription use only. It is intended for use in patients aged 12 to 64 presenting to urgent or emergency care settings with signs and symptoms of acute respiratory infection, within seven days of symptom onset and within three days of fever onset. Results are not intended as a stand-alone diagnostic and must be interpreted in the context of other clinical findings. FebriDx does not identify specific pathogens or determine severity of illness.

References

1. Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient setting. JAMA Netw Open, 2022, 5(10): e2234588.
2. U.S. Food and Drug Administration. 510(k) summary for FebriDx Bacterial/Non-Bacterial Point-of-Care Assay. K230917.